Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer

Rashed Ghandour, Nirmish Singla, Yair Lotan

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Muscle-invasive bladder cancer (MIBC) represents 25% of newly diagnosed bladder cancer. MIBC is aggressive and requires timely management. The current standard of care is neoadjuvant chemotherapy followed by radical cystectomy, an approach that could result in significant morbidities. Modifications in the chemotherapy regimens, as well as in perioperative care and surgical approach, have resulted in better overall toxicity profile and faster recovery. However, bladder-preservation in carefully selected patients can lead to acceptable oncological outcomes and better quality of life. Optimization of bladder-preservation protocols and proper identification of patients who tolerate and respond to various treatment modalities will significantly impact patient survival in the coming future.

Original languageEnglish (US)
Pages (from-to)426-439
Number of pages14
JournalTrends in Cancer
Issue number7
StatePublished - Jul 2019


  • epidemiology
  • muscle-invasive bladder cancer
  • outcomes
  • perioperative chemotherapy
  • radical cystectomy
  • trimodality therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this